|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Clark PE, Spiess PE, Agarwal N, Bangs R,
Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander
T, Greenberg RE, et al: NCCN Guidelines Insights: Bladder Cancer,
Version 2.2016. J Natl Compr Cancer Netw. 14:1213–1224. 2016.
View Article : Google Scholar
|
|
4
|
Babjuk M, Burger M, Zigeuner R, Shariat
SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A,
Palou Redorta J, et al European Association of Urology: EAU
guidelines on non-muscle-invasive urothelial carcinoma of the
bladder: Update 2013. Eur Urol. 64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abufaraj M, Gust K, Moschini M, Foerster
B, Soria F, Mathieu R and Shariat SF: Management of muscle
invasive, locally advanced and metastatic urothelial carcinoma of
the bladder: A literature review with emphasis on the role of
surgery. Transl Androl Urol. 5:735–744. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Witjes JA, Compérat E, Cowan NC, De Santis
M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG and Sherif A: AU
guidelines on muscle-invasive and metastatic bladder cancer:
summary of the 2013 guidelines. Eur Urol. 65:778–792. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bidnur S, Savdie R and Black PC:
Inhibiting immune checkpoints for the treatment of bladder cancer.
Bladder Cancer. 2:15–25. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Djebali S, Davis CA, Merkel A, Dobin A,
Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F,
et al: Landscape of transcription in human cells. Nature.
489:101–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Oncol.
13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Enokida H, Yoshino H, Matsushita R and
Nakagawa M: The role of microRNAs in bladder cancer. Investig Clin
Urol. 57(Suppl 1): S60–S76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen J, Miao Z, Xue B, Shan Y, Weng G and
Shen B: Long non-coding RNAs in urologic malignancies: Functional
roles and clinical translation. J Cancer. 7:1842–1855. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li HJ, Li X, Pang H, Pan JJ, Xie XJ and
Chen W: Long non-coding RNA UCA1 promotes glutamine metabolism by
targeting miR-16 in human bladder cancer. Jpn J Clin Oncol.
45:1055–1063. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu H, Li X, Song Y, Zhang P, Xiao Y and
Xing Y: Long non-coding RNA ANRIL is up-regulated in bladder cancer
and regulates bladder cancer cell proliferation and apoptosis
through the intrinsic pathway. Biochem Biophys Res Commun.
467:223–228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li LJ, Zhu JL, Bao WS, Chen DK, Huang WW
and Weng ZL: Long noncoding RNA GHET1 promotes the development of
bladder cancer. Int J Clin Exp Pathol. 7:7196–7205. 2014.PubMed/NCBI
|
|
16
|
Zhu YP, Bian XJ, Ye DW, Yao XD, Zhang SL,
Dai B, Zhang HL and Shen YJ: Long noncoding RNA expression
signatures of bladder cancer revealed by microarray. Oncol Lett.
7:1197–1202. 2014.PubMed/NCBI
|
|
17
|
Schmitt AM and Chang HY: Long noncoding
RNAs in cancer pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bartonicek N, Maag JL and Dinger ME: Long
noncoding RNAs in cancer: Mechanisms of action and technological
advancements. Mol Cancer. 15:432016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang C, Li X, Zhao H and Liu H: Long
non-coding RNAs: Potential new biomarkers for predicting tumor
invasion and metastasis. Mol Cancer. 15:622016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sheppard KE and McArthur GA: The
cell-cycle regulator CDK4: An emerging therapeutic target in
melanoma. Clin Cancer Res. 19:5320–5328. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bertoli C, Skotheim JM and de Bruin RA:
Control of cell cycle transcription during G1 and S phases. Nat Rev
Mol Cell Biol. 14:518–528. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Um HD: Bcl-2 family proteins as regulators
of cancer cell invasion and metastasis: A review focusing on
mitochondrial respiration and reactive oxygen species. Oncotarget.
7:5193–5203. 2016. View Article : Google Scholar :
|
|
23
|
Gibson CJ and Davids MS: BCL-2 antagonism
to target the intrinsic mitochondrial pathway of apoptosis. Clin
Cancer Res. 21:5021–5029. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo H, German P, Bai S, Barnes S, Guo W,
Qi X, Lou H, Liang J, Jonasch E, Mills GB, et al: The PI3K/AKT
pathway and renal cell carcinoma. J Genet Genomics. 42:343–353.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nitulescu GM, Margina D, Juzenas P, Peng
Q, Olaru OT, Saloustros E, Fenga C, Spandidos DA, Libra M and
Tsatsakis AM: Akt inhibitors in cancer treatment: The long journey
from drug discovery to clinical use (Review). Int J Oncol.
48:869–885. 2016.
|
|
26
|
Lee JJ, Loh K and Yap YS: PI3K/Akt/mTOR
inhibitors in breast cancer. Cancer Biol Med. 12:342–354. 2015.
|
|
27
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
